CLOs on the Move


 
Innovacon, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

PamLab

Pamlab, L.L.C. is a company focused on the future. We lead the United States with use of novel folate therapies to lower homocysteine. We are looking for hard-working, motivated and optimistic individuals who would like a challenging career and are

Sss Co

Sss Co is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Saluda Medical

Saluda Medical is a global medical device company focused on patient outcomes, science, and engineering to transform the neuromodulation industry with a platform of closed-loop technologies that optimize therapy by reading, recording, and responding to the nerves' response to stimulation` The company's first product, Evoke®, is the only ECAP-controlled closed-loop spinal cord stimulation (SCS) system designed to treat chronic pain, a condition that affects more than 540 million people globally` SCS treats the condition by stimulating the spinal cord and altering the transmission of pain signals to the brain` Saluda's proprietary Evoke System is the only closed-loop SCS system designed to maintain individualized, consistent therapy by precisely controlling spinal cord activation through real-time customization of waveforms on every evoked compound action potential (ECAP) at the same rate as the stimulation frequency (At stimulation frequency of 40 Hz, 40 adjustments are made each second, 3`5 million adjustments per day, and 1`2 billion adjustments per year)`

Team Wellness Center

Team Mental Health Services is dedicated to enhancing the well-being of individuals by providing an array of comprehensive behavioral and physical services in an environment that promotes quality of life, continuous improvement and social awareness. ...

Innocrin Pharmaceuticals

Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.